Search for: "Abbvie" Results 1 - 20 of 366
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
7 Nov 2017, 7:36 am by Jay W. Belle Isle
Jeffrey Konrad in his suit against Big Pharma giant AbbVie, agreeing with Mr. [read post]
15 Oct 2014, 5:04 am by CorporateAcquisitions MergerLawBlogger
The AbbVie board is apparently reconsidering whether to continue its inversion deal with Shire now that Treasury has reduced the economic incentives to do the deal. [read post]
10 Jul 2014, 9:59 pm by Patent Docs
Janssen Biotech, Inc., the Federal Circuit affirmed judgments by the District Court for the District of Massachusetts in infringement and interference actions involving AbbVie Deutschland GmbH & Co., KG; AbbVie Bioresearch Center, Inc.; and AbbVie Biotechnology Ltd. [read post]
26 Aug 2020, 6:12 am by Sara E. Teller
Federal agency reaches settlement with AbbVie in fraud case. [read post]
5 Dec 2016, 11:17 am by Daily Record Staff
Designed to build strong collaboration between AbbVie and Johns Hopkins Medicine researchers, the agreement will focus on several areas of oncology research, ... [read post]
10 Aug 2020, 1:16 pm by Angela Mauroni
The settlement’s requirements for AbbVie to change its marketing practices for HUMIRA are only enforceable in the state of California. [read post]
18 Oct 2014, 5:19 am by Paul Caron
The $1.64 billion termination fee AbbVie would owe Shire for nixing their takeover deal is tax-deductible, experts say. [read post]
27 Jun 2019, 3:19 am by Paul Caron
Allergan’s income will generate some U.S. taxes because of a deal announced Tuesday for AbbVie... [read post]
23 Dec 2014, 6:10 pm by Jon Gelman
He said that AbbVie had made that affordable by offering “a significant discount. [read post]
10 Aug 2022, 5:27 am by Sara E. Teller
Abbvie's proposed deal will open the door for Teva to settle its opioid case. [read post]
4 Oct 2017, 4:15 am by Steve Brachmann
The post Patent settlement between AbbVie and Amgen delays Humira generic until 2023 appeared first on IPWatchdog.com | Patents & Patent Law. [read post]
19 May 2021, 2:15 pm by Eileen McDermott
Yesterday, Representatives Carolyn Maloney (D-NY), Jerrold Nadler (D-NY) and David Cicilline (D-RI) asked Federal Trade Commission (FTC) Acting Chair Rebecca Kelly Slaughter to open a formal inquiry into pharmaceutical company AbbVie’s practices, which the representatives said have worked “to delay U.S. biosimilar entry for [AbbVie’s] blockbuster drug Humira. [read post]